Selection of blockbuster announcements
1. Hanrui Cobalt, the largest cobalt powder producer in China, once again submitted to the Hong Kong Stock Exchange.
On December 27th, Nanjing Hanrui Cobalt Co., Ltd. (Hanrui Cobalt, 300618.SZ) once again submitted its form to the Hong Kong Stock Exchange, with China International Capital Corporation as its exclusive sponsor. It is reported that since March 6, 2017, Hanrui Cobalt's A shares have been listed on the growth Enterprise Market of Shenzhen Stock Exchange.
2、$Nuocheng Jianhua-B (09969.HK) $From July to September, the sales volume of Obutini is about 73.9729 million yuan.
Nuocheng Jianhua-B reported that in the three months ended September 30, 2021, the company had achieved sales of about RMB 73.9729 million.
3、$Cornerstone Pharmaceutical-B (02616.HK) $Application for accurate targeting drug AYVAKIT ®for gastrointestinal stromal tumors to be approved in Hong Kong, China
Cornerstone Pharmaceutical-B announced that AYVAKIT ®(avapritinib), the first of its kind in gastrointestinal stromal tumors (GIST), has been approved for marketing in Hong Kong, China, to treat adult patients with unresectable or metastatic gastrointestinal stromal tumors with PDGFRA D842V mutations.
4、$Broad Pharmaceutical (00512.HK) $Strategic cooperation with Germany's ITM, 520 million euros layout of three global innovative RDC drugs
Broad Pharmaceutical announced that it has reached a product strategic cooperation with Germany's ITM Isotope Technologies Munich SE, whereby Broad Pharmaceuticals will pay a license signing fee and milestone payment of no more than 520 million euros to obtain the exclusive development, production and commercialization rights and interests of TOCscan ®, ITM-11 and ITM-41 in Greater China (Chinese mainland, Hong Kong, Macau, and Taiwan), three innovative radionuclide coupling drugs (RDC) developed by ITM.
5、China Huarong (02799.HK) $It is proposed to transfer 1.091 billion yuan to Ningbo Bank of Huarong Consumer Finance.
China Huarong announced that the company plans to transfer its 70% stake in Huarong Consumer Finance Co., Ltd. (Huarong Consumer Finance). After the completion of this equity transfer, Huarong Consumer Finance is no longer consolidated for the company's subsidiaries and the Group's consolidated financial statements.
6、$China Mobile Limited (00941.HK) $The result of A-share issue was disclosed, and the abandoned purchase amount exceeded 700 million.
On the evening of December 27th, China Mobile Limited disclosed the results of the offering. Online investors subscribed 12.91 million shares unpaid and abandoned 743 million yuan, while offline investors, including institutions, subscribed 220000 shares unpaid and abandoned 12.7049 million yuan. The total amount of abandoned purchases online and offline has created another history of abandoned purchases, surpassing Postal Savings Bank of China's historical record of 653 million yuan two years ago.
Listing of new shares
Hanrui Cobalt, the largest cobalt powder producer in China, once again reported that the HKEx's past performance fluctuations are significantly expanding the three major production lines.
Cloud Music (09899): the over-allotment option expires at the end of the stable price period.
Important matters
Nuocheng Jianhua-B (09969): sales of Obutinib from July to September are about 73.9729 million yuan.
Cornerstone Pharmaceutical-B (02616): application for accurate targeting drug AYVAKIT ®for gastrointestinal stromal tumors approved in Hong Kong, China
Peijia Medical-B (09996): HighLife transatrial septal mitral valve replacement system scientific research clinical trial successfully completed in China's first patient implantation
Baiyunshan (00874): evaluation of the consistency of quality and efficacy of norfloxacin capsules
The trial of opening up the pharmaceutical industry-B _ (09939) protamine in the treatment of COVID-19 's non-hospitalized patients was not statistically significant.
Broad Pharmaceutical (00512) has reached a strategic cooperation with Germany's ITM, with a layout of 520 million euros for three globally innovative RDC drugs.
Tengshengbo drug-B (02137): the first patient administration has been completed in the BRII-179 (VBI2601) 2a/2b phase clinical trial of chronic hepatitis B virus patients.
Zijin Mining Group (02899): the first phase of Julong Copper Project in Tibet is completed and put into production in 2022, which is expected to produce 12-130000 tons of copper.
Hehong Service (06093) plans to acquire 68.75% equity of Jinning property Management in Zunyi City with 91.45 million yuan.
Jinke Service (09666): plans to acquire all shares of Jinke Hotel Management Company with 312 million yuan.
Hyundai Dental (03600) plans to acquire 70% stake in Malaysia Digital Dental Laboratory
China National Building Material (03323) set up two joint venture companies to build a new energy-saving and environmental protection wall material production base in Chizhou.
China Huarong (02799) plans to transfer 70% equity of Huarong Consumer Finance to Ningbo Bank by 1.091 billion yuan.
Guolian Securities (01456): Xinye Construction plans to transfer 5.8227 million shares of the company to Wuxi Industrial Group for free.
The subsidiary of Xiamen Port Administration (03378) recently received a total of 22.8871 million yuan in government awards.
AH interaction
China Mobile Limited (00941) disclosed that the abandoned purchase amount of A-share issue exceeded 700 million.
BeiGene, Ltd. (06160): about 115 million A shares will be issued at the end of the over-allotment option exercise period.
Additional placement
Zheng Meiji (00564): 4.7223 million exercising shares will be listed and circulated on December 31st.
Change of equity
Fudan Zhangjiang (01349): deputy General Manager Li Jun completes the reduction of 1.79726 million A shares
Personnel change
China Telecom Corporation (00728): Zhu Min resigned as Executive Director, Executive Vice President, Chief Financial Officer, etc.